Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency

Mdxhealth SA (NASDAQ: MDXH) received a notification from Nasdaq on July 20, 2026, indicating non-compliance with the minimum market value requirement of $35 million for continued listing on The Nasdaq Capital Market. The company has until January 19, 2027 (180 calendar days) to regain compliance by achieving a market value exceeding $35 million for at least 10 consecutive business days. The deficiency does not currently impact the company's listing status, and business operations remain unaffected.

07/24/2026, 4:59 PM • GlobeNewswire

Mdxhealth Reports Q1-2026 Results

Mdxhealth (NASDAQ: MDXH) reported Q1-2026 revenue of $27.4 million, up 13% year-over-year, but announced the discontinuation of its Resolve UTI business and Plano, Texas laboratory operations due to uncertain reimbursement landscape and a Medicare policy reversal. The company is refocusing on its core prostate cancer diagnostics business and establishing updated 2026 guidance of $110-115 million in revenue (20-26% YoY growth). The company also faces a $10.4 million Medicare recoupment decision from Novitas that it is contesting.

05/13/2026, 4:00 PM • GlobeNewswire

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

Mdxhealth announced positive data from the GPS-ProMPT study at the EAU Congress, demonstrating that its Genomic Prostate Score (GPS mdx) test successfully stratified treatment failure risk across multiple prostate cancer treatment pathways. The study of 409 patients showed excellent six-year freedom-from-failure outcomes (92-100%), supporting the test's ability to identify patients with favorable tumor biology for treatment de-escalation. The company is advancing collaboration with University of Oxford on the GPS-ProtecT study to establish GPS mdx as the first genomic classifier supported by randomized clinical trial evidence.

03/16/2026, 4:00 PM • GlobeNewswire

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

MDxHealth SA (NASDAQ: MDXH), a precision diagnostics company, announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, followed by a conference call. The company also reported preliminary 2025 revenues, issued 2026 guidance, and amended earnout terms with Exact Sciences. Additionally, MDxHealth is collaborating with the University of Oxford to validate its GPS test in a large randomized trial for localized prostate cancer treatment.

02/12/2026, 5:00 PM • GlobeNewswire

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

MDxHealth reported preliminary 2025 revenues of $109 million (21% YoY growth) with Q4 revenues of $30.5 million (23% YoY growth). The company issued 2026 revenue guidance of $137-140 million (26-28% growth) and expects to achieve a 10% adjusted EBITDA margin run rate by year-end 2026. MDxHealth amended its earnout obligations with Exact Sciences, deferring payments to 2026-2028 and issuing 3 million warrant shares at $5.265 per share.

01/12/2026, 8:00 AM • GlobeNewswire

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

Mdxhealth announced a collaboration with the University of Oxford to initiate Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial, the world's largest randomized clinical trial for localized prostate cancer treatment. This study aims to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance cohort, potentially impacting clinical practice guidelines and payer coverage.

01/06/2026, 8:00 AM • GlobeNewswire

Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne

MDxHealth has completed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which includes the ExoDx Prostate test and related assets, with payments structured over four years.

09/15/2025, 5:29 PM • Benzinga

Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

MDxHealth appointed Michael Holder to its Board of Directors as Audit Committee Chair, replacing Regine Slagmulder. CFO Ron Kalfus is resigning, with Scott McMahan assuming interim CFO responsibilities.

07/03/2025, 1:00 PM • GlobeNewswire